- Home
- MTVA vs IINN Comparison
MTVA vs IINN Comparison
Compare MTVA & IINN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- IINN
- Stock Information
- Founded
- MTVA 2014
- IINN 2018
- Country
- MTVA United States
- IINN Israel
- Employees
- MTVA N/A
- IINN N/A
- Industry
- MTVA
- IINN Medical/Dental Instruments
- Sector
- MTVA
- IINN Health Care
- Exchange
- MTVA NYSE
- IINN Nasdaq
- Market Cap
- MTVA 14.3M
- IINN 13.7M
- IPO Year
- MTVA N/A
- IINN 2021
- Fundamental
- Price
- MTVA $0.71
- IINN $1.41
- Analyst Decision
- MTVA Strong Buy
- IINN Strong Buy
- Analyst Count
- MTVA 2
- IINN 1
- Target Price
- MTVA $7.50
- IINN $2.00
- AVG Volume (30 Days)
- MTVA 64.8K
- IINN 1.7M
- Earning Date
- MTVA 08-13-2025
- IINN 08-14-2025
- Dividend Yield
- MTVA N/A
- IINN N/A
- EPS Growth
- MTVA N/A
- IINN N/A
- EPS
- MTVA N/A
- IINN N/A
- Revenue
- MTVA N/A
- IINN N/A
- Revenue This Year
- MTVA N/A
- IINN N/A
- Revenue Next Year
- MTVA N/A
- IINN N/A
- P/E Ratio
- MTVA N/A
- IINN N/A
- Revenue Growth
- MTVA N/A
- IINN N/A
- 52 Week Low
- MTVA $0.60
- IINN $0.40
- 52 Week High
- MTVA $4.36
- IINN $1.65
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- IINN 61.38
- Support Level
- MTVA N/A
- IINN $1.28
- Resistance Level
- MTVA N/A
- IINN $1.46
- Average True Range (ATR)
- MTVA 0.00
- IINN 0.16
- MACD
- MTVA 0.00
- IINN -0.01
- Stochastic Oscillator
- MTVA 0.00
- IINN 51.02
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
About IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.